These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38160286)

  • 1. Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapies.
    Joisa CU; Chen KA; Beville S; Stuhlmiller T; Berginski ME; Okumu D; Golitz BT; East MP; Johnson GL; Gomez SM
    Pac Symp Biocomput; 2024; 29():276-290. PubMed ID: 38160286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapies.
    Joisa CU; Chen KA; Beville S; Stuhlmiller T; Berginski ME; Okumu D; Golitz BT; Johnson GL; Gomez SM
    bioRxiv; 2023 Aug; ():. PubMed ID: 37577663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
    Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated single-dose kinome profiling data is predictive of cancer cell line sensitivity to kinase inhibitors.
    Joisa CU; Chen KA; Berginski ME; Golitz BT; Jenner MR; Herrera Loeza G; Yeh JJ; Gomez SM
    PeerJ; 2023; 11():e16342. PubMed ID: 38025707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
    Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.
    van der Noord VE; van der Stel W; Louwerens G; Verhoeven D; Kuiken HJ; Lieftink C; Grandits M; Ecker GF; Beijersbergen RL; Bouwman P; Le Dévédec SE; van de Water B
    Breast Cancer Res; 2023 May; 25(1):51. PubMed ID: 37147730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
    Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
    Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A targeted quantitative proteomics strategy for global kinome profiling of cancer cells and tissues.
    Xiao Y; Guo L; Wang Y
    Mol Cell Proteomics; 2014 Apr; 13(4):1065-75. PubMed ID: 24520089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Triple Drug Combination That Is Synergistically Cytotoxic for Triple-Negative Breast Cancer Cells Using a Novel Combination Discovery Approach.
    Ahmad S; He Q; Williams KP; Scott JE
    SLAS Discov; 2020 Sep; 25(8):923-938. PubMed ID: 32441190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinome inhibition states and multiomics data enable prediction of cell viability in diverse cancer types.
    Berginski ME; Joisa CU; Golitz BT; Gomez SM
    PLoS Comput Biol; 2023 Feb; 19(2):e1010888. PubMed ID: 36809237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
    Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrated framework for identification of effective and synergistic anti-cancer drug combinations.
    Sharma A; Rani R
    J Bioinform Comput Biol; 2018 Oct; 16(5):1850017. PubMed ID: 30304987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance.
    Krayem M; Aftimos P; Najem A; van den Hooven T; van den Berg A; Hovestad-Bijl L; de Wijn R; Hilhorst R; Ruijtenbeek R; Sabbah M; Kerger J; Awada A; Journe F; Ghanem GE
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32098410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression.
    Tran TP; Ong E; Hodges AP; Paternostro G; Piermarocchi C
    BMC Syst Biol; 2014 Jun; 8():74. PubMed ID: 24961498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
    Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
    Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
    Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
    Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
    Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.